This modification of the GE11 peptide allowed oridonin to achieve specific recognition of EGFR-overexpressing esophageal cancer cells and improve anticancer efficiency through pathways such as cell cycle blockade, disruption of mitochondrial membrane potential, and activation of apoptosis signaling pathways. This evidence concerns the gene EGFR and esophageal cancer.